Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
News about Chimerix, Inc. (NASDAQ: CMRX) centers on its work as a biopharmaceutical company developing medicines for patients facing deadly diseases, with a particular focus on rare and high-grade brain tumors. Recent press releases emphasize the company’s lead clinical program, dordaviprone (ONC201), in development for H3 K27M-mutant diffuse glioma.
Investors and followers of CMRX news will find updates on key regulatory milestones, including the U.S. Food and Drug Administration’s acceptance of Chimerix’s New Drug Application for dordaviprone in recurrent H3 K27M-mutant diffuse glioma, Priority Review status, and the assigned PDUFA target action date of August 18, 2025. Company news also highlights Rare Pediatric Disease Designation, Fast-Track Designation, and Orphan Drug Designation for dordaviprone in multiple regions.
Chimerix news releases describe ongoing clinical development activities, such as the Phase 3 ACTION trial in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation, and Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetic data. Additional items include corporate events like participation in oncology and precision medicine forums and updates on equity inducement grants under Nasdaq Listing Rule 5635(c)(4).
Another major theme in recent CMRX coverage is the definitive agreement for Jazz Pharmaceuticals to acquire Chimerix for approximately $935 million in cash. News articles outline the transaction terms, expected closing timing subject to customary conditions, and how dordaviprone would fit within Jazz’s rare oncology portfolio. For readers tracking CMRX, this news stream provides a view into Chimerix’s clinical progress, regulatory interactions, and announced strategic transaction with Jazz.
Chimerix (NASDAQ:CMRX) announced a live conference call on February 25, 2021, at 8:30 a.m. ET to discuss its fourth-quarter and full-year financial results ending December 31, 2020. The call will include a business overview, with access available via phone or webcast. Chimerix focuses on developing medicines for serious diseases, with ongoing programs for BCV, ONC201, and DSTAT. Notably, BCV is under review for regulatory approval, and ONC201 is in a registrational trial for glioma. The company remains committed to advancing innovative therapies, reflecting its dedication to patients.
Chimerix, a biopharmaceutical company, has successfully closed its public offering of common stock, selling 13,529,750 shares at $8.50 each, yielding gross proceeds of $115 million. This follows the underwriters' full exercise of their option to purchase additional shares. The net proceeds will be allocated to fund clinical development of product candidates, pre-launch activities, and general corporate purposes. Jefferies and Cowen served as joint bookrunners for the offering. The securities were offered under an effective SEC registration statement.
Chimerix, a biopharmaceutical company (Nasdaq: CMRX), has priced its public offering of 11,765,000 shares at $8.50 each, aiming to raise approximately $100 million before expenses. This offering, expected to close around January 25, 2021, has an additional 30-day option for underwriters to purchase up to 1,764,750 shares. Proceeds will fund clinical developments, commercial activities, and general expenses. Jefferies and Cowen are leading this offering, with securities filed under SEC registration. Chimerix focuses on innovative treatments for cancer and serious diseases.
Chimerix, Inc. (Nasdaq: CMRX) has announced plans to offer up to $75 million in common stock through an underwritten public offering, with an additional $11.25 million option for underwriters. Proceeds will fund clinical development, commercial pre-launch activities, and general corporate purposes. Jefferies and Cowen are managing the offering. The offering is subject to market conditions and is made under a previously filed shelf registration statement with the SEC. Completion timing and terms remain uncertain.
Chimerix (NASDAQ:CMRX) has announced the acquisition of Oncoceutics, a privately-held company developing ONC201, a promising therapy for recurrent H3 K27M-mutant glioma. This acquisition, costing $78 million, positions Chimerix to advance its oncology portfolio, with ONC201 showing a compelling overall response rate of at least 20% in early trials. A regulatory pathway for potential approval is outlined, addressing a market opportunity exceeding $500 million. Upcoming milestones include a confirmatory data analysis expected in 2021 and a PDUFA date for another treatment in April.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced CEO Mike Sherman will present at the H.C. Wainwright BioConnect 2021 Conference, available on January 11, 2021, at 7:00 a.m. ET. This pre-recorded presentation will be accessible via the Investor Relations section of Chimerix's website for 90 days.
Chimerix is focused on developing medicines for serious diseases, with key programs including dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is in trials for acute lung injury related to COVID-19 and acute myeloid leukemia, while BCV seeks regulatory approval as a smallpox countermeasure.
Chimerix (NASDAQ:CMRX) announced that the FDA has accepted the New Drug Application (NDA) for brincidofovir (BCV) as a countermeasure for smallpox. The FDA granted Priority Review status, aiming for a decision by April 7, 2021. BCV has shown antiviral activity against smallpox in animal studies and is backed by funding from BARDA. The Priority Review designation reduces the review time from 10 months to a target of 6 months, suggesting the treatment may significantly improve safety or effectiveness for this serious condition.
Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Credit Suisse 29th Annual Healthcare Conference on November 12, 2020, at 4:15 p.m. ET. This event will be available via live audio webcast on Chimerix's Investor Relations website and archived for 90 days. The company is advancing innovative medicines for cancer and serious diseases, focusing on two clinical-stage programs: dociparstat sodium (DSTAT) and brincidofovir (BCV), with DSTAT currently in trials for COVID-19 and acute myeloid leukemia.
Chimerix (CMRX) achieved major milestones in Q3 2020, including completing NDA submissions for brincidofovir (BCV) as a smallpox countermeasure. The company anticipates FDA notification regarding submission acceptance and a PDUFA date by year-end. Expected milestones include initiating a Phase 3 AML trial in early 2021 and a potential procurement contract with BARDA. Financially, Chimerix reported a net loss of $11.4 million, improved from $73.7 million in Q3 2019, with revenues of $1.6 million, down from $2.0 million. The company maintains a healthy balance sheet with $87.8 million available.
Chimerix (CMRX) will host a conference call on November 5, 2020, at 8:30 a.m. ET to report Q3 2020 financial results and provide a business overview. The company focuses on innovative medicines for cancer and serious diseases, with key products including dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is under Phase 2/3 trials for COVID-19 related acute lung injury and has an agreed Phase 3 protocol for acute myeloid leukemia. Stakeholders can access the call via phone or webcast, with details available on the company's website.